Cevec Pharmaceuticals GmbH

Cevec Pharmaceuticals GmbH provides advanced biomanufacturing solutions, specializing in the production of biologics and therapeutic proteins through proprietary cell line technology. Founded in 2003, Cevec Pharmaceuticals GmbH is based in Cologne, Germany, focusing on the development and production of biologics. The company has engaged in eight funding deals, with the most recent funding round being a Series C in October 2022, raising EUR 4. 50 mn, which brought the total amount raised to EUR 4.

50 mn. The company was founded by Ulrich Schraermeyer, and Frank Ubags and Wolfgang Kintzel currently serve as CEOs. Cevec specializes in advanced biomanufacturing solutions, particularly focusing on the development and production of biologics and therapeutic proteins. Their core offerings include a proprietary cell line technology that enables the efficient production of complex proteins crucial for the pharmaceutical industry.

This technology enhances yield and reduces production time, addressing significant challenges faced by companies developing biologic medications. Cevec serves a diverse clientele that includes biotech companies and pharmaceutical firms across North America and Europe, specifically in Germany, the United States, and the United Kingdom. Their solutions are utilized in creating therapeutic agents for various diseases in both clinical and commercial settings. Cevec's revenue model is primarily based on B2B transactions through partnerships with pharmaceutical and biotechnology organizations.

These partnerships often include licensing agreements and service contracts for the use of their proprietary technologies in biologic manufacturing. Clients may enter into multi-year contracts for continuous access to Cevec’s capabilities, facilitating ongoing production as they develop their therapeutic pipelines. The company's flagship technology, centered around their unique cell line platform, is pivotal in driving revenue through its adoption by industry players seeking to improve production efficiencies. In October 2022, Cytiva Software acquired Cevec Pharmaceuticals GmbH for an undisclosed amount, which allows Cytiva access to scalable production cell lines for vectors based on adeno-associated viruses and adenoviruses.

Moving forward, Cevec plans to expand its product offerings and market presence. The funding raised in the Series C round will support the development of new products targeting enhancements in biologics manufacturing, as well as expansion into additional markets in Europe and North America by the end of 2023.